Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
order: 1 piece Delivery by Sep 23 19 sold Guangzhou Zhuangji Biotechnology Co., Ltd
Here are some recent analyst ratings: Barclays issued a "Overweight" rating on 01/05/2026 BMO Capital issued a "Outperform" rating on 11/13/2025 Needham issued a "Buy" rating on 11/07/2025 Evercore ISI Group issued a "Outperform" rating on 11/07/2025 Canaccord Genuity issued a "Buy" rating on 08/08/2025 To track analyst ratings and price targets for $OMDA, check out Quiver Quantitative's $OMDA forecast page
This therapy is ideal for individuals looking to boost their antioxidant defenses and improve overall health
The low RSD suggested the high reproducibility and reliability of the measurement
In addition to expanded indications, pharmaceutical companies are developing next-generation therapies that combine GLP-1 activity with other mechanisms
US$ 27.84
US$ 28.04
US$ 24.84
US$ 23.10
US$ 28.04
US$ 23.45
US$ 20.80
